(Reuters) – Eli Lilly (NYSE:) expects to start selling its weight-loss drug in Hong Kong as early as the end of this year, Bloomberg News reported on Sunday.
The company has received the Hong Kong government approval to sell its tirzepatide injections — branded as Mounjaro — in a device called Kwikpen for both long-term weight management and type 2 diabetes, Eli Lilly told Bloomberg in a statement.
When it comes to securing your child’s financial future, choosing the best UGMA/UTMA accounts is crucial. In this article, we’ll...
Grace Kelly’s Cartier diamond. Mariah Carey’s 35-carat sparkler. Kim Kardashian’s flawless cushion-cut stone. These aren’t just engagement rings—they’re symbols of...
Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., August 14, 2025....
Award recognizes accomplished female leaders whose examples set a foundation across all levels of a company’s supply chain network SAN...
The New York Stock Exchange on Aug. 26, 2025.Brendan McDermid | ReutersThe August jobs report on Friday is expected to...
In this webinar - IDC’s Research Director, Mobile Phones, Anthony Scarsella, joins B-Stock’s VP of Mobile, Sean Cleland, to discuss...
The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.
